MedTrace Logo

Fever After Misoprostol Administration for the Treatment of Primary Postpartum Hemorrhage

NCT01080846 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2010-11-11

No results posted yet for this study

Summary

This study will evaluate side effects after sublingual misoprostol (600 mcg) as a first-line treatment for primary postpartum hemorrhage (PPH) due to suspected uterine atony.

Conditions

  • Postpartum Hemorrhage

Interventions

DRUG

Misoprostol

600 mcg of sublingual misoprostol

Sponsors & Collaborators

  • Bill and Melinda Gates Foundation

    collaborator OTHER

  • University of Liverpool

    collaborator OTHER

  • Gynuity Health Projects

    lead OTHER

Principal Investigators

  • Beverly Winikoff, MD, MPH · Gynuity Health Projects

  • Andrew Weeks, MD · The University of Liverpool

  • Wilfrido Leon, MD · HOSPITAL GINECO OBSTETRICO ISIDRO AYORA

  • Gustavo Barrera, MD · HOSPITAL GINECO OBSTETRICO ISIDRO AYORA

  • Jill Durocher · Gynuity Health Projects

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
14 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-02-28
Primary Completion
2010-08-31
Completion
2010-08-31

Countries

  • Ecuador

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01080846 on ClinicalTrials.gov